Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Current Assets (2019 - 2025)

Outset Medical (OM) has disclosed Current Assets for 7 consecutive years, with $250.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 2.84% to $250.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $250.9 million, a 2.84% decrease, with the full-year FY2025 number at $250.9 million, down 2.84% from a year prior.
  • Current Assets was $250.9 million for Q4 2025 at Outset Medical, down from $265.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $448.0 million in Q2 2021 to a low of $250.9 million in Q4 2025.
  • A 5-year average of $323.7 million and a median of $309.7 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: increased 18.47% in 2021, then decreased 28.46% in 2022.
  • Outset Medical's Current Assets stood at $409.8 million in 2021, then dropped by 8.82% to $373.6 million in 2022, then fell by 22.06% to $291.2 million in 2023, then fell by 11.33% to $258.2 million in 2024, then dropped by 2.84% to $250.9 million in 2025.
  • Per Business Quant, the three most recent readings for OM's Current Assets are $250.9 million (Q4 2025), $265.4 million (Q3 2025), and $275.6 million (Q2 2025).